JP6706147B2 - Sanitary absorbent article - Google Patents

Description

The present invention relates to a sanitary absorbent article.

Generally, the absorbent body of all used absorbent articles contains a superabsorbent polymer. However, if the content of the superabsorbent polymer is increased, the hardness of the superabsorbent polymer and the uneven shape due to the arrangement of the superabsorbent polymer impair the wearing feeling. Further, if the content of the superabsorbent polymer is reduced so as not to impair the feeling of wearing, the absorption capacity is small, and the body fluid once absorbed may return.

As another technique other than this, a technique is known in which an agent that acts on blood itself to change the state of blood is applied to an absorbent article to improve various performances of the absorbent article. Patent Document 1 discloses a napkin containing a partially hydrated dicarboxylic acid anhydride copolymer or a polycation as a blood gelling agent. Patent Document 2 proposes a personal care absorbent article containing a triblock polymer containing polypropylene oxide and polyethylene oxide or a polycation as a fluid treatment material.

JP-A-57-153648 Special table 2002-528232 gazette

In the absorbent article described in Patent Document 1, it is described that the blood gelling agent is provided on the liquid permeation blocking material, but there is a risk that the separated liquid component may leak due to diffusion on the liquid permeation blocking material. .. On the other hand, in Patent Document 2, the red blood cell mass is trapped between the fibers of the non-woven web, but it is difficult to continuously ensure the absorption of blood by the mechanism. Further, in Patent Document 1 and Patent Document 2, there is no description regarding the configuration in which the sheet containing the fluid treatment agent is provided separately from the topsheet, the absorber and the backsheet.

Therefore, the subject of this invention is providing the sanitary absorbent article which can eliminate the fault which the prior art mentioned above has.

The present invention is a sanitary absorbent article comprising an absorbent body containing pulp, and a topsheet and a backsheet that are located on the side of the wearer's skin facing surface that sandwiches the absorbent body. Between the back sheet and the back sheet, comprising a hemagglutination agent-containing sheet containing a hemagglutination agent, the absorber is formed of an absorbent sheet, on the skin-facing surface of the hemagglutination agent-containing sheet, It is intended to provide a sanitary absorbent article in which a multi-layer structure formed of the absorbent sheet is arranged.

According to the sanitary absorbent article of the present invention, it is difficult to impair the feeling of wearing, it is possible to absorb body fluid quickly and sufficiently, and it is possible to effectively prevent the body fluid once absorbed from returning.

FIG. 1 is a plan view of a sanitary napkin which is a preferred embodiment of the sanitary absorbent article of the present invention. FIG. 2 is a plan view showing the skin-facing surface side (surface sheet side) of the absorbent body and the aggregating agent-containing sheet of the sanitary napkin shown in FIG. FIG. 3 is a sectional view schematically showing a section taken along the line III-III in FIG. 1. FIG. 4 is an enlarged cross-sectional view of an absorbent body and a coagulant-containing sheet included in the sanitary napkin shown in FIG. FIG. 5 is a perspective view of a topsheet included in the sanitary napkin shown in FIG. 1. FIG. 6 is an enlarged cross-sectional view of an absorbent body and a coagulant-containing sheet included in a sanitary absorbent article according to another embodiment of the present invention.

Hereinafter, a sanitary absorbent article of the present invention (hereinafter, also simply referred to as an absorbent article) will be described with reference to the drawings based on a sanitary napkin 1 (hereinafter, also referred to as “napkin 1”) that is a preferred embodiment thereof. Explain. The napkin 1 includes an absorber 4 containing pulp, and a topsheet 2 and a backsheet 3 that sandwich the absorber 4 and are located on the side of the wearer's skin-facing surface. Further, the napkin 1 includes a hemagglutination agent-containing sheet 80 containing the hemagglutination agent 8 between the topsheet 2 and the backsheet 3. FIG. 1 shows a plan view of a napkin 1 which is a preferred embodiment of the sanitary absorbent article of the present invention, and FIG. 2 shows the absorbent body 4 and the hemagglutination agent-containing sheet 80 shown in FIG. The top view which shows the skin facing surface side (top sheet side) of is shown. FIG. 3 shows a cross-sectional view of the napkin 1. The sanitary absorbent article of the present invention is preferable for menstrual blood absorption.

In the napkin 1, as shown in FIGS. 2 and 3, the absorbent body 4 is formed of an absorbent sheet, and specifically, the absorbent sheet is a multilayer structure in which a plurality of layers are stacked in the thickness direction. .. In the napkin 1, the absorbent body 4 formed of the absorbent sheet contains the superabsorbent polymer 41 and pulp. In the present embodiment, the napkin 1 is interposed between the liquid-permeable topsheet 2 forming the skin-facing surface, the backsheet 3 forming the non-skin-facing surface, and the two sheets 2 and 3 and is formed from the absorbent sheet. It has an absorptive main body 10 provided with the absorbent body 4 as described above.

As shown in FIG. 1, the absorbent main body 10 of the napkin 1 includes an excretory portion facing portion B that is arranged to face the excretory portion (vaginal opening, etc.) of the wearer when worn, and a wearer portion than the excretory portion opposing portion B. Has a front portion A disposed closer to the ventral side (front side) and a rear portion C disposed closer to the wearer's back side (rear side) than the excretion portion facing portion B. The napkin 1 and the absorbent main body 10 have a vertical direction X corresponding to the front-back direction of the wearer and a horizontal direction Y orthogonal to the vertical direction X. That is, the absorbent main body 10 is divided in the longitudinal direction X in the order of the front part A, the excretion part facing part B, and the rear part C.

In addition, in the present specification, the skin-facing surface is a surface of the napkin 1 or a constituent member thereof (eg, the topsheet 2) that faces the skin side of the wearer when the napkin 1 is worn, and the non-skin-facing surface is the napkin. 1 or a component thereof, which is a surface facing the side opposite to the skin side (clothing side) when the napkin 1 is worn. Therefore, it does not necessarily mean that the skin-facing surface contacts the wearer's skin. Further, the vertical direction X coincides with the longitudinal direction of the napkin 1 and the absorbent main body 10, and the transverse direction Y coincides with the width direction of the napkin 1 and the absorbent main body 10 (direction orthogonal to the longitudinal direction).

In the present embodiment, as shown in FIGS. 1 and 3, in addition to the absorbent main body 10, the napkin 1 is further laterally extended from both side portions of the excretion portion facing portion B of the absorbent main body 10 along the vertical direction X. It has a pair of wing portions 10W, 10W extending outward of Y.

In the sanitary absorbent article of the present invention, when the excretion section facing section B has the wing section 10W like the napkin 1 of the present embodiment, the longitudinal direction of the absorbent article (the longitudinal direction of the absorbent article). , (In the X direction in the drawing) means a region having a wing portion 10W (a region sandwiched by a root of one wing portion 10W along the longitudinal direction X and a root of the other wing portion 10W along the longitudinal direction X). .. The excretion part facing portion B in the absorbent article having no wing portion is generated when the absorbent article is folded in three-fold individual packaging form, and the absorbent article is laterally (in the width direction of the absorbent article; With respect to two folding curves (not shown) that cross in the Y direction), it means a region surrounded by the first folding curve and the second folding curve counted from the front end in the longitudinal direction X of the absorbent article. To do.

In the napkin 1 of the present embodiment, as shown in FIG. 1, the topsheet 2 covers the entire skin-facing surface of the absorbent body 4 and extends from both side edges of the absorbent body 4 in the vertical direction X to the outside in the horizontal direction Y. It is extended to. On the other hand, the back sheet 3 covers the entire non-skin-facing surface of the absorber 4, and further extends outward in the lateral direction Y from both side edges of the absorber 4 along the longitudinal direction X, and a side sheet 7 described later. Together with this, a side flap portion 10S is formed. The topsheet 2 and the backsheet 3 are joined to each other by a known joining means such as an adhesive, heat sealing, ultrasonic sealing, or the like at a portion extending from both edges of the absorbent body 4 in the longitudinal direction X. In addition, each of the topsheet 2 and the backsheet 3 and the absorber 4 may be joined by an adhesive.

In the napkin 1, as shown in FIGS. 1 and 3, the side sheets 7 are arranged on both sides of the skin-facing surface of the absorbent main body 10 (the skin-facing surface of the topsheet 2) along the vertical direction X. Suitably, the side seat|sheet 7 is distribute|arranged over the full length of the vertical direction X of the absorptive main body 10 so that it may overlap with the both right and left sides along the vertical direction X of the absorber 4 in planar view.

In the napkin 1, as shown in FIG. 1, the pair of side sheets 7 and 7, respectively, has a linear first joining line 61 located in the excretion part facing portion B and a longitudinal direction X of the first joining line 61. Are joined to the topsheet 2 with linear second joining lines 62 located in front of and behind (front portion A and rear portion C). In the napkin 1, the first joining line 61 has a curved shape that is convex outward in the horizontal direction Y in a plan view, and the second joining lines 62 extend so as to alternately intersect in the vertical direction in a plan view. It is linear (zigzag linear). Thus, when the side sheet 7 is joined to the topsheet 2 at the first joining line 61 and the second joining line 62 and fixed to the skin-facing surface of the absorbent main body 10, as shown in FIG. A space P defined by the side sheet 7 and the top sheet 2 is formed inward of the first joining line 61 and the second joining line 62 in the lateral direction Y. Since the space portion P is open toward the center of the absorbent main body 10 in the lateral direction Y, body fluid such as menstrual blood flowing outward from the center of the absorbent body 10 is stored in the space portion P. As a result, leakage of body fluid can be effectively prevented. It should be noted that elastic members that are stretched in the vertical direction X may be arranged at the free ends of the pair of side seats 7, 7 to arrange a pair of leakproof cuffs along the vertical direction X. The leak-proof cuff has an upright property and can prevent lateral leakage of menstrual blood disposed on the skin-facing surface.

In the napkin 1, as shown in FIG. 1, the side flap portion 10S largely protrudes outward in the lateral direction Y at the excretion portion facing portion B, and thereby the left and right sides along the longitudinal direction X of the absorbent main body 10 are provided. A pair of wings 10W, 10W are provided on both sides.

The wing portion 10W is used by being folded back to the non-skin facing surface side of the crotch portion of clothing such as shorts. In the napkin 1, as shown in FIG. 1, the wing portion 10W has a substantially trapezoidal shape in which a lower bottom (a side longer than the upper bottom) is located on a side portion along the longitudinal direction X of the absorbent main body 10 in a plan view. It has a shape. On the non-skin facing surface of the wing portion 10W, a wing portion adhesive portion (not shown) for fixing the wing portion 10W (napkin 1) to clothes (not shown) such as shorts is formed. By using the adhesive portion, the wing portion 10W folded back to the non-skin facing surface (outer surface) side of the crotch portion of the clothing can be adhesively fixed to the crotch portion during use. A non-skin facing surface of the absorbent main body 10 is also provided with a main body adhesive section (not shown) for fixing the absorbent main body 10 to clothes such as shorts.

As shown in FIGS. 1 and 3, in the napkin 1, the topsheet 2 and the absorber 4 are integrally formed on the skin-facing surface of the absorbent body 10 (the skin-facing surface of the topsheet 2) toward the backsheet 3 side. It is provided with a linear squeezing groove 9 which is recessed in. Therefore, the compressed groove 9 is a groove in which the density of each fiber that is a constituent member of the surface sheet 2 and the absorber 4 is higher than the density of the peripheral portion of the groove. “Linear” in the linear compression groove 9 means that the shape of the groove (concave portion) is not limited to a straight line in plan view, and includes a curved line. Each line may be a continuous line or a discontinuous line such as a broken line. For example, the squeeze groove 9 may be composed of a row of a large number of discontinuous point embosses.

In the napkin 1, as viewed in plan as shown in FIG. 1, the compression groove 9 has a first lateral compression groove 91 extending in the lateral direction Y in the front portion A and the rear portion C, and both sides of the excretion portion facing portion B. And a vertical compression groove 92 extending in the vertical direction X. In the napkin 1, the first lateral compression grooves 91 in the front portion A and the rear portion C extend in the lateral direction Y while forming a convex curved shape outward in the longitudinal direction X. Further, each vertical compression groove 92 extends in the vertical direction X while forming a convex curved shape inward in the horizontal direction Y on a side portion of the excretion portion facing portion B along the vertical direction X. In the napkin 1, the first lateral compression groove 91 of the front part A, one vertical compression groove 92, the first lateral compression groove 91 of the rear part C, and the other vertical compression groove 92 are connected to form a ring-shaped circumferential groove. Is forming. In addition, in the napkin 1, the pressing groove 9 has second lateral pressing grooves 93, 93 extending in the lateral direction Y inward in the vertical direction X with respect to the first lateral pressing groove 91 in the front portion A and the rear portion C, respectively. Have In the napkin 1, the second lateral compression grooves 93, 93 of the front portion A and the rear portion C have a curved shape that is convex outward in the vertical direction X. The second lateral pressing grooves 93, 93 of the napkin 1 are not connected to the pair of vertical pressing grooves 92, 92 as shown in FIG. 1, but may be connected. The squeeze groove 9 thus formed can suppress the diffusion of the body fluid flowing in the plane direction on the topsheet 2 and can effectively prevent the liquid leakage from the periphery of the napkin 1.

As shown in FIG. 3, the napkin 1 is provided with a hemagglutination agent-containing sheet 80 containing the hemagglutination agent 8 between the topsheet 2 and the backsheet 3. The hemagglutination agent-containing sheet 80 may be arranged at least in the excretion part facing portion B, and may be arranged in a region overlapping with the upper absorbent sheet 402a of the central absorbent sheet 402 described later, but in the napkin 1, The main absorbent sheet 401, which will be described later, that constitutes the absorbent body 4 is arranged in a larger area than the front-side absorbent sheet 401a. Suitably, the width (length in the lateral direction Y) of the hemagglutination agent-containing sheet 80 of the napkin 1 is the same as the width (length in the lateral direction Y) of the surface-side absorbent sheet 401a constituting the absorber 4. It is almost the same. Further, the hemagglutination agent-containing sheet 80 of the napkin 1 has a length in the longitudinal direction X longer than the length of the surface-side absorbent sheet 401a constituting the absorber 4 in the longitudinal direction X, and the longitudinal direction X of the napkin 1 is longer than the longitudinal direction X. Are distributed over the entire length of. Thus, the hemagglutination agent-containing sheet 80 covers the entire non-skin-facing surface of the absorbent body 4.

The hemagglutination agent 8 included in the napkin 1 has a function of aggregating red blood cells in blood. At that time, it is desirable to use a substance that acts so as to separate the plasma component from the agglutinated aggregate of red blood cells. A particularly desirable hemagglutination agent is one that has a property of at least two or more red blood cells aggregating to form an agglutinate when the blood fluidity is maintained when 1000 ppm is added to the pseudo blood. Here, "the state in which the fluidity of blood is maintained" means that 10 g of pseudo blood to which 1000 ppm of the measurement sample agent was added was a screw tube bottle (Product No. "Screw tube No. 4" manufactured by Maru-M, Inc., inner diameter 14.5 mm, It means a state in which 60% or more of pseudo blood flows down within 20 seconds when the screw tube bottle in which the pseudo blood is put is turned over 180 degrees after being placed in a body diameter of 27 mm and a total length of 55 mm). The pseudo blood means that the viscosity measured using a B-type viscometer (Model No. TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement condition: rotor No. 19, 30 rpm, 25° C., 60 seconds) is 8 mPa·s. In addition, the blood cell/plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Institute Co., Ltd.) was prepared. Further, whether or not “two or more red blood cells aggregate to form an aggregate” is determined as follows. That is, the pseudo blood to which 1000 ppm of the measurement sample agent was added was diluted 4000 times with physiological saline, and a laser diffraction/scattering particle size distribution analyzer (manufactured by HORIBA, model number: LA-950V2, measurement condition: flow cell) The average median diameter of the volume particle diameters measured at a temperature of 25° C. by a laser diffraction/scattering method (measurement, circulation velocity 1, without ultrasonic waves) corresponds to the size of an aggregate formed by aggregation of two or more red blood cells. When it is 10 μm or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.

The hemagglutination agent 8 contained in the hemagglutination agent-containing sheet 80 contains a cationic polymer. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride starch. The hemagglutination agent 8 can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as the cationic polymer. In the present invention, the “quaternary ammonium salt” includes a compound having a positive monovalent charge at the position of a nitrogen atom, or a compound which produces a positive monovalent charge at the position of a nitrogen atom by neutralization. However, specific examples thereof include salts of quaternary ammonium cations, neutralized salts of tertiary amines, and tertiary amines bearing a cation in an aqueous solution. The “quaternary ammonium site” described below is also used in the same meaning and is a site that is positively charged in water. Further, in the present invention, the "copolymer" is a polymer obtained by copolymerizing two or more kinds of polymerizable monomers, and a binary copolymer and a copolymer of ternary or more. Includes both things. In the present invention, the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more kinds of monomers. When the hemagglutination agent 8 contains a quaternary ammonium salt homopolymer and/or a quaternary ammonium salt copolymer and/or a quaternary ammonium salt polycondensate as a cationic polymer, the hemagglutination agent 8 is , A quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, and a quaternary ammonium salt polycondensate, or any combination of two or more thereof. You can leave. The quaternary ammonium salt homopolymers may be used alone or in combination of two or more. Similarly, the quaternary ammonium salt copolymer may be used alone or in combination of two or more. Further, similarly, the quaternary ammonium salt polycondensate can be used alone or in combination of two or more kinds. In the present specification, the term "hemocyte aggregating agent" means a single compound capable of aggregating red blood cells of blood, or a plurality of combinations of the single compounds, or a combination of a plurality of compounds to agglutinate red blood cells. It is an agent that develops. In other words, the hemagglutination agent is an agent limited to those having hemagglutination. Therefore, when the hemagglutination agent contains the third component, it is referred to as a hemagglutination agent composition to be distinguished from the hemagglutination agent. The term "single compound" as used herein is a concept that includes compounds having the same composition formula but different molecular weights due to the different number of repeating units.

Among the various cationic polymers described above, it is particularly preferable to use a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate from the viewpoint of adsorbability to red blood cells. preferable. In the following description, for the sake of simplicity, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

The quaternary ammonium salt homopolymer is obtained by polymerizing one kind of polymerizable monomer having a quaternary ammonium moiety. On the other hand, the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It is obtained by using seeds and copolymerizing these. That is, the quaternary ammonium salt copolymer is obtained by copolymerizing two or more kinds of polymerizable monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety has a quaternary ammonium moiety. It is obtained by using one or more kinds of polymerizable monomers that it has and one or more kinds of polymerizable monomers that do not have a quaternary ammonium moiety, and copolymerizing these. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by using a condensate composed of at least one monomer having a quaternary ammonium moiety and polymerizing the condensate. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing two or more kinds of condensates of monomers having a quaternary ammonium moiety, or a quaternary ammonium moiety. It is obtained by polycondensation of a condensate composed of at least one monomer having a quaternary monomer and at least one monomer having no quaternary ammonium moiety.

The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium site. The quaternary ammonium site can be generated by quaternary ammoniumation of a tertiary amine with an alkylating agent. Alternatively, the tertiary amine can be dissolved in an acid or water and neutralized. Alternatively, it can be produced by quaternary ammonium conversion by a nucleophilic reaction including a condensation reaction. Examples of the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. Of these alkylating agents, the use of dialkyl sulfate is preferable because it does not cause the problem of corrosion that may occur when an alkyl halide is used. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, hyaluronic acid and the like. .. In particular, it is preferable to use a quaternary ammonium salt polymer in which the tertiary amine moiety is converted to a quaternary ammonium with an alkylating agent, because the electric double layer of red blood cells can be reliably neutralized. The quaternary ammonium conversion by a nucleophilic reaction including a condensation reaction can be performed by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin, a cyclization reaction of dicyandiamide and diethylenetriamine.

As a result of the study by the present inventor, it was found that the use of a cationic polymer is particularly effective for producing an aggregate of red blood cells in menstrual blood. The reason for this is as follows. Red blood cells have a red blood cell membrane on their surface. The red blood cell membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton, which is the lower layer, and a lipid film, which is the upper layer. The lipid film exposed on the surface of red blood cells contains a protein called glycophorin. Glycophorin has a sugar chain, to which an anion-charged sugar is bound, called sialic acid, at its end. As a result, red blood cells can be treated as colloidal particles with anionic charges. An aggregating agent is generally used for aggregating the colloidal particles. Considering that red blood cells are anionic colloidal particles, it is advantageous to use a cationic substance as the aggregating agent in terms of neutralizing the electric double layer of red blood cells. Further, when the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the red blood cells are likely to be entangled with each other, which promotes the aggregation of the red blood cells. Furthermore, when the aggregating agent has a functional group, the agglutination of red blood cells is also promoted by the interaction between the functional groups, which is preferable.

From the viewpoint of effectively producing aggregates of red blood cells, the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is at least these values, the entanglement of the cationic polymers between the red blood cells and the crosslinking of the cationic polymer between the red blood cells are sufficiently caused. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and further preferably 3 million or less. When the molecular weight of the cationic polymer is below these values, the cationic polymer is well dissolved in menstrual blood. The molecular weight of the cationic polymer is preferably 2000 or more and 10 million or less, more preferably 2000 or more and 5 million or less, further preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable that it is 30,000 or more and 3 million or less. The molecular weight referred to in the present invention is a weight average molecular weight. Further, two or more kinds of cationic polymers having different molecular weights may be combined within the above-mentioned molecular weight range. The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. The specific measurement conditions are as follows. As the column, a column in which a guard column α manufactured by Tosoh Corporation and an analytical column α-M are connected in series is used at a column temperature of 40°C. RI (refractive index) is used for the detector. As the measurement sample, 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent. As the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent obtained by dissolving 150 mmol/L sodium sulfate and 1% by mass acetic acid in water is used. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is used in 10 mL of the eluent to obtain a pullulan having a molecular weight of 5900, a pullulan having a molecular weight of 47300, a pullulan having a molecular weight of 212,000, and a pullulan having a molecular weight of 788,000. Pullulan, a pullulan mixture dissolved 2.5 mg each, is used as a molecular weight standard. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL/min and an injection rate of 100 μL. Elution with 50 mmol/L of lithium bromide and 1% by mass of acetic acid dissolved in ethanol:water=3:7 (volume ratio) except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate. Use liquid. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, polyethylene glycol (PEG) having a molecular weight of 106, PEG having a molecular weight of 400, PEG having a molecular weight of 1470, PEG having a molecular weight of 6450 is used in 20 mL of the eluent. , Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 87,000, and a PEG-PEO mixture having 10 mg dissolved therein are used as molecular weight standards. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL/min and the injection rate is 100 μL.

From the viewpoint of more effectively generating aggregates of red blood cells, when a quaternary ammonium salt polymer is used as the cationic polymer, the quaternary ammonium salt polymer preferably has a streaming potential of 1500 μeq/L or more. , 2000 μeq/L or more, more preferably 3000 μeq/L or more, still more preferably 4000 μeq/L or more. When the streaming potential of the quaternary ammonium salt polymer is at least these values, the electric double layer of red blood cells can be sufficiently neutralized. The upper limit of the streaming potential is preferably 13000 μeq/L or less, more preferably 8000 μeq/L or less, and even more preferably 6000 μeq/L or less. When the streaming potential of the quaternary ammonium salt polymer is below these values, electrical repulsion between the quaternary ammonium salt polymers adsorbed on the red blood cells can be effectively prevented. The streaming potential of the quaternary ammonium salt polymer is preferably 1500 μeq/L or more and 13000 μeq/L or less, more preferably 2000 μeq/L or more and 13000 μeq/L or less, and 3000 μeq/L or more and 8000 μeq/L or less. It is more preferable that it is 4000 μeq/L or more and 6000 μeq/L or less. The streaming potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituent cationic monomer itself and the molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. It can be controlled. The streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. The specific measurement conditions are as follows. First, the hot melt that adheres each member to a commercially available napkin is invalidated by using a dryer or the like, and decomposed into members such as a top sheet, an absorber, and a back sheet. A multi-step solvent extraction method from a non-polar solvent to a polar solvent is performed on each decomposed member to separate the treating agent used for each member to obtain a solution containing a single composition. The obtained solution is dried and solidified, 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography), fluorescent X-ray, etc. are combined to identify the structure of the treating agent. For a measurement sample obtained by dissolving 0.001 g of the treatment agent (quaternary ammonium salt polymer) to be measured in 10 g of physiological saline, 0.001 N aqueous solution of sodium polyethylene sulfonate (when the measurement sample has a negative charge) , 0.001 N polydiallyldimethylammonium chloride aqueous solution) is titrated to measure the titration amount XmL required until the potential difference between the electrodes disappears. Then, the streaming potential of the quaternary ammonium salt polymer is calculated by the formula 1.
Streaming potential = (X+0.190*)×1000 ・・・Equation 1
(* Titration required for solvent saline)

In order for the cationic polymer to be successfully adsorbed on the surface of red blood cells, it is advantageous that the cationic polymer is susceptible to interaction with sialic acid present on the surface of red blood cells. From this point of view, when the present inventors proceeded with the study, the value of the inorganic value/organic value which is the ratio of the inorganic value and the organic value of the substance (hereinafter referred to as “IOB (Inorganic Organic Balance) value”). It was found that the degree of interaction between the sialic acid-bound product and the cationic polymer can be evaluated by using as a scale. In particular, it has been found to be advantageous to use, as the cationic polymer, those having an IOB value which is equal to or close to that of the sialic acid conjugate. The sialic acid-bonded product is a compound in which sialic acid can exist in the living body, and examples thereof include compounds in which sialic acid is bonded to the terminal of glycolipid such as galactolipid.

In general, the properties of a substance are largely controlled by various intermolecular forces between molecules, and the intermolecular forces mainly consist of Van Der Waals force due to molecular mass and electric affinity due to polarity of molecules. If the Van Der Waals force, which has a large effect on changes in the properties of substances, and the electrical affinity can be individually grasped, the properties of unknown substances or their mixtures can be predicted from their combinations. be able to. This idea is a theory well known as "organic conceptual diagram theory". As for the organic conceptual diagram theory, for example, "Organic Analysis" by Minoru Fujita (Kaniya Shoten, 1952), "Organic Qualitative Analysis: Systematic. Pure Things" by Minoru Fujita (Kyoritsu Publishing, 1953), Minoru Fujita The book "Reorganized Chemistry Experiments-Organic Chemistry" (Kawade Shobo, 1971), Akira Fujita and Masami Akatsuka "Systematic Organic Qualitative Analysis (Mixtures)" (Kazama Shobo, 1974), and Yoshio Koda It is described in detail in Shiro Sato and Yoshio Honma, "New Edition Organic Conceptual Diagram: Basics and Applications" (Sankyo Publishing, 2008). In the organic conceptual diagram theory, regarding the physicochemical properties of substances, the degree of physical properties mainly due to Van Der Waals force is called “organic”, and the degree of physical properties mainly due to electrical affinity is called “inorganic”, The physical properties of a substance are considered as a combination of "organic" and "inorganic". Then, one carbon (C) is defined as organic 20, and the inorganic and organic values of various polar groups are defined as shown in Table 1 below, and the sum of the inorganic values and the organic The sum of the values is calculated and the ratio of the two is defined as the IOB value. In the present invention, the IOB value of the above-mentioned sialic acid conjugate is determined based on these organic value and inorganic value, and the IOB value of the cationic polymer is determined based on the value.

Specifically, when the cationic polymer is a homopolymer, the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated. When polydiallyldimethylammonium chloride is used as the cationic polymer, an organic value of -C-x8=160, an inorganic value of Ammo and NH4 saltx1=400, and a ring (non-aromatic single ring) Since it has an inorganic value of x1=10, an organic value of -Clx1=40 and an inorganic value of 10, the total inorganic value is 400+10+10=420, and the total organic value is 160+40. =200. Therefore, the IOB value is 420/200=2.10.

On the other hand, when the cationic polymer is a copolymer, the IOB value is calculated according to the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from the monomer A and the monomer B, the organic value of the monomer A is ORA, the inorganic value is INA, the organic value of the monomer B is ORB, and the inorganic value is INB. If the monomer A/monomer B molar ratio is MA/MB, the IOB value of the copolymer is calculated from the following formula.

The IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, and 2.2. The above is more preferable. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and further preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. And more preferably 2.2 or more and 3.0 or less. The IOB value of sialic acid is 4.25 for sialic acid alone, and 3.89 for sialic acid conjugate. The sialic acid-bound product is a product in which a sugar chain in a glycolipid is bound to sialic acid, and the sialic acid-bound product has a higher ratio of organic value and a lower IOB value than sialic acid alone.

The IOB value of the cationic polymer is as described above, but the organic value itself is preferably 40 or more, more preferably 100 or more, and further preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, further preferably 240 or less, and further preferably 190 or less. For example, the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, further preferably 100 or more and 240 or less, and further preferably 130 or more and 190 or less. By setting the organic value of the cationic polymer in this range, the cationic polymer will be more successfully adsorbed to red blood cells.

On the other hand, the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, even more preferably 100 or more, even more preferably 120 or more, and 250 or more. Is particularly preferable. Further, it is preferably 790 or less, more preferably 750 or less, even more preferably 700 or less, even more preferably 680 or less, and particularly preferably 490 or less. For example, the inorganic value is preferably 70 or more and 790 or less, more preferably 90 or more and 750 or less, even more preferably 90 or more and 680 or less, still more preferably 120 or more and 680 or less, It is particularly preferably 250 or more and 490 or less. By setting the inorganic value of the cationic polymer in this range, the cationic polymer will be more successfully adsorbed to red blood cells.

From the viewpoint of more successfully adsorbing the cationic polymer to red blood cells, it is preferable that x and y satisfy the following formula A, where x is an organic value and y is an inorganic value of the cationic polymer.
y=ax (A)
In the formula, a is preferably 0.66 or more, more preferably 0.93 or more, still more preferably 1.96 or more. Further, a is preferably 4.56 or less, more preferably 4.19 or less, and further preferably 3.5 or less. For example, a is preferably a number of 0.66 or more and 4.56 or less, more preferably a number of 0.93 or more and 4.19 or less, and a number of 1.96 or more and 3.5 or less. Is more preferable. In particular, if the organic value and inorganic value of the cationic polymer are within the above range, if the organic value and inorganic value of the cationic polymer satisfy the above formula A, the cation Of the cationic polymer is more likely to interact with the sialic acid conjugate, and the cationic polymer is more likely to be adsorbed to red blood cells.

The cationic polymer is preferably water-soluble from the viewpoint of effectively forming an aggregate of red blood cells. In the present invention, “water-soluble” means that 100 g of a glass beaker (5 mmΦ) is mixed with 0.05 g of powdered cationic polymer having a thickness of 1 mm or less or a film-like cationic polymer having a thickness of 0.5 mm or less in 50 mL of ion exchange water at 25° C. At this time, a stirrer chip having a length of 20 mm and a width of 7 mm was put in, and the total amount thereof was dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by As One Co., Ltd. In the present invention, as a more preferable solubility, the total amount is preferably dissolved in water within 3 hours, more preferably the total amount is dissolved within water within 30 minutes.

The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded to it. The quaternary ammonium moiety is preferably present on the side chain. In this case, if the main chain and the side chain are bonded at a single point, the flexibility of the side chain is less likely to be hindered, and the quaternary ammonium site present in the side chain smoothly moves to the surface of red blood cells. It will be adsorbed. However, in the present invention, it is not prevented that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, “bonded at one point” means that one of the carbon atoms constituting the main chain is single-bonded to one carbon atom located at the end of the side chain. .. "Binding at two or more points" means that two or more of the carbon atoms constituting the main chain are each single-bonded to two or more carbon atoms located at the end of the side chain. Say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded to it, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded to it In the case of, the carbon number of each side chain is preferably 4 or more, more preferably 5 or more, and further preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and further preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and even more preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium site (cation site) in the side chain, and even if the anion that is the counter ion contains carbon, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the above range. It is preferable because the polymer has less steric hindrance when adsorbed on the surface of red blood cells.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include polymers of vinyl monomers having a quaternary ammonium moiety or a tertiary amine moiety. .. When a vinyl-based monomer having a tertiary amine moiety is polymerized, a quaternary ammonium salt homopolymer obtained by quaternizing the tertiary amine moiety with an alkylating agent before and/or after the polymerization is used. Becomes a polymer, becomes a tertiary amine neutralized salt in which the tertiary amine moiety is neutralized with an acid before and/or after polymerization, or becomes a cation-bearing tertiary amine in an aqueous solution after polymerization. .. Examples of the alkylating agent and the acid are as described above.

Particularly, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine. In addition, a side chain having a quaternary ammonium moiety is bonded to the main chain at one point, poly(2-methacryloxyethyldimethylamine quaternary salt), poly(2-methacryloxyethyltrimethylammonium salt). ), poly(2-methacryloxyethyldimethylethylammonium methylsulfate), poly(2-acryloxyethyldimethylamine quaternary salt), poly(2-acryloxyethyltrimethylamine quaternary salt), poly(2-acryloxy) Ethyl dimethyl ethyl ammonium ethyl sulfate), poly(3-dimethylaminopropylacrylamide quaternary salt), dimethylaminoethyl polymethacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropylacrylamide, polyamidine and the like. Be done. On the other hand, examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, two kinds of polymerizable monomers used for the above-mentioned quaternary ammonium salt homopolymer are used as the copolymer. The copolymer obtained by the above-mentioned copolymerization can be used. Alternatively, as the quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium site are used. It is possible to use a copolymer obtained by copolymerizing one or more compounds. Furthermore, in addition to the polymerizable vinyl monomer, or alternatively, other polymerizable monomers, e.g., -SO ₂ - or the like can be used. As described above, the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.

In particular, the quaternary ammonium salt copolymer having the repeating unit represented by the above formula 1 and the repeating unit represented by the following formula 2 effectively produces an aggregate of red blood cells. It is preferable from the viewpoint.

Moreover, as the polymerizable monomer having no quaternary ammonium moiety, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, by using a cationic polymerizable monomer or a nonionic polymerizable monomer, charge canceling with the quaternary ammonium site in the quaternary ammonium salt copolymer is possible. As a result, the agglutination of red blood cells can be effectively caused. Examples of the cationically polymerizable monomer include vinyl pyridine as a cyclic compound having a nitrogen atom bearing a cation under a specific condition, and a linear compound having a nitrogen atom bearing a cation under a specific condition in its main chain. Examples thereof include a condensation compound of dicyandiamide and diethylenetriamine. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, styrenesulfonic acid, and salts of these compounds. On the other hand, examples of the nonionic polymerizable monomer include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate and methyl. Examples thereof include acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate and butyl acrylate. One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. You can Further, two or more kinds of cationic polymerizable monomers can be used in combination, two or more kinds of anionic polymerizable monomers can be used in combination, or two or more kinds of nonionic polymerizable monomers can be combined. Can also be used. The quaternary ammonium salt copolymer obtained by copolymerizing a cationic polymerizable monomer, an anionic polymerizable monomer and/or a nonionic polymerizable monomer as the polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymers exemplified below).

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrogen bonding can also be used. When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using the quaternary ammonium salt copolymer obtained therefrom, a hard aggregate tends to be generated, and The absorption performance is even less likely to be hindered. The functional group capable of hydrogen bonding, for example _{-OH, -NH 2, -CHO, -COOH} , -HF, such as -SH and the like. Examples of the polymerizable monomer having a functional group capable of hydrogen bonding, hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethyl acrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, Examples thereof include hydroxyethyl methacrylate and hydroxyethyl acrylate. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like, which have a strong hydrogen bond, are preferable because the adsorbed state of the quaternary ammonium salt polymer on red blood cells is stabilized. These polymerizable monomers may be used alone or in combination of two or more.

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effects as in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding, that is, the hardness of red blood cells An effect is obtained that aggregates are easily generated. Examples of the functional group capable of hydrophobic interaction include an alkyl group such as a methyl group, an ethyl group and a butyl group, a phenyl group, an alkylnaphthalene group and a fluorinated alkyl group. Examples of the polymerizable monomer having a functional group capable of hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate and styrene. Is mentioned. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc., which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed on the erythrocyte of the quaternary ammonium salt polymer. Is stable, which is preferable. These polymerizable monomers may be used alone or in combination of two or more.

The molar ratio of the polymerizable monomer having a quaternary ammonium moiety to the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium moiety. It is preferable that the ammonium salt copolymer is appropriately adjusted so that red blood cells are sufficiently aggregated. Alternatively, it is preferable that the streaming potential of the quaternary ammonium salt copolymer is adjusted to the above-mentioned value. Alternatively, it is preferable that the IOB of the quaternary ammonium salt copolymer is adjusted to the above-mentioned value. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol%. % Or more, and more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, further preferably 65 mol% or less, and further preferably 56 mol% or less. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, It is more preferably 32 mol% or more and 65 mol% or less, and further preferably 38 mol% or more and 56 mol% or less.

When the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, a condensate composed of one or more monomers having a quaternary ammonium moiety described above is used as the polycondensate. A polycondensate obtained by polymerizing those condensates can be used. Specific examples thereof include dicyandiamide/diethylenetriamine polycondensate and dimethylamine/epichlorohydrin polycondensate.

The above-mentioned quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl-based polymerizable monomer. As the polymerization method, for example, radical polymerization, living radical polymerization, living cationic polymerization, living anionic polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used. There are no particular restrictions on the polymerization conditions, and the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and/or IOB value can be obtained may be appropriately selected.

The cationic polymer described in detail above is an example of the above-mentioned "preferred hemagglutination agent 8", and its effect can be referred to in Examples 1 to 45 of Japanese Patent Application No. 2015-239286.

Further, as the hemagglutination agent 8 included in the napkin 1, as described above, in addition to the polycation (cationic polymer), a composition containing a third component, for example, a solvent, a plasticizer, a fragrance, a skin care agent ( It may be provided in the form of a hemagglutination agent composition). The components other than the cationic polymer that can be contained in the hemagglutination agent 8 can be used alone or in combination of two or more. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol or the like can be used. As the fragrance, there can be used fragrances having a green herbal-like odor described in Japanese Patent No. 4776407, plant extract, citrus extract, and the like. As the skin care agent, the plant extract, collagen, natural moisturizing component, moisturizing agent, keratin softening agent, anti-inflammatory agent, etc. described in Japanese Patent No. 4084278 can be used.

The proportion of the cationic polymer in the hemagglutination composition is preferably 1% by mass or more, more preferably 3% by mass or more, and even more preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and further preferably 10% by mass or less. For example, the ratio of the cationic polymer is preferably 1% by mass or more and 50% by mass or less, more preferably 3% by mass or more and 30% by mass or less, and further preferably 5% by mass or more and 10% by mass or less. preferable. By setting the ratio of the cationic polymer in the hemagglutination composition within this range, it is possible to impart an effective amount of the cationic polymer to the absorbent article.

FIG. 4 shows an enlarged sectional view of the absorbent body 4 and the hemagglutination agent-containing sheet 80 in the sectional view shown in FIG. As described above, in the napkin 1, as shown in FIGS. 3 and 4, the hemagglutination agent 8 is arranged on the hemagglutination agent-containing sheet 80. The thickness of the hemagglutination agent-containing sheet 80 on which the hemagglutination agent 8 is arranged is preferably 0.1 mm or more, particularly 0.5 mm or more, and preferably 3 mm or less, particularly 1.5 mm or less. preferable. More specifically, it is preferably 0.1 mm or more and 3 mm or less, and particularly preferably 0.5 mm or more and 1.5 mm or less from the viewpoint of obtaining an absorbent article having a good wearing feeling. The thickness of the hemagglutination agent-containing sheet 80 is measured by the following method.

<Method of measuring thickness of hemagglutination agent-containing sheet 80>
The hemagglutination agent-containing sheet 80, which is an object to be measured, is allowed to stand in a horizontal place without wrinkles or bending, and the thickness is measured under a load of 5 cN/cm ² . A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) was used for measuring the thickness in the present invention. At this time, a plate having a circular shape or a square shape in plan view (an acrylic plate having a thickness of about 5 mm) is arranged between the tip portion of the thickness gauge and the measurement portion of the measurement object, and the load is 5 cN/cm ² . Adjust the plate size so that

In the napkin 1, the hemagglutination agent 8 disposed on the hemagglutination agent-containing sheet 80 exists on the skin-facing surface side and the non-skin-facing surface side of the hemagglutination agent-containing sheet 80, respectively, as shown in FIG. .. The amount of the hemagglutination agent 8 contained in the hemagglutination agent-containing sheet 80 is preferably 0.1 g/m ² or more, more preferably 0.5 g/m ² or more, and 1.5 g/m 2. More preferably, it is ² or more. Further, it is preferably 25 g/m ² or less, more preferably 15 g/m ² or less, and further preferably 10 g/m ² or less. For example, the amount of the hemagglutination agent 8 in the hemagglutination agent-containing sheet 80 is preferably 0.1 g/m ² or more and 25 g/m ² or less, and 0.5 g/m ² or more and 15 g/m ² or less. It is more preferably 1.5 g/m ² or more and 10 g/m ² or less. By applying the hemagglutination agent 8 to the hemagglutination agent-containing sheet 80 in an amount within this range, the excreted red blood cells in the blood can be effectively aggregated. It is particularly preferable that the hemagglutination agent 8 is a cationic polymer and the amount of the cationic polymer contained in the hemagglutination agent-containing sheet 80 is within the above range.

Whether or not the hemagglutination agent 8 is arranged on the hemagglutination agent-containing sheet 80 can be determined as follows, for example.
By using an energy dispersive X-ray analyzer (EDX) attached to a scanning electron microscope (SEM), elemental analysis of each of the constituent fibers constituting the hemagglutination agent-containing sheet 80 and the hemagglutination agent 8 is performed in advance. Next, a sample piece for which it is desired to determine whether or not the hemagglutination agent 8 is placed is attached to an aluminum sample table using a carbon double-sided tape, and platinum/vanadium coating is performed as necessary, and then SEM observation While expanding, the presence or absence of an element in the hemagglutination agent 8 is confirmed using an EDX (elemental analyzer). The measurement is performed with an acceleration voltage of 15 kV to 40 kV.

In the napkin 1, as shown in FIGS. 3 and 4, the multilayer structure formed of the absorbent sheet constituting the absorbent body 4 is arranged on the skin-facing surface of the hemagglutination agent-containing sheet 80. In the napkin 1, one absorbent sheet has a superabsorbent polymer 41 dispersedly arranged in three dimensions and constituent fibers containing pulp. The absorbent sheet has a polymer-rich region PT in which the mass ratio of the superabsorbent polymer 41 to the total amount of the mass of the constituent fibers containing pulp and the mass of the superabsorbent polymer 41 is relatively high in a cross-sectional view, It has a fiber rich region FT relatively lower than the polymer rich region PT. In the napkin 1, the polymer-rich region PT and the fiber-rich region FT are divided in the thickness direction of the absorbent body 4 made of an absorbent sheet. The absorbent sheet has an integral structure in which the superabsorbent polymer 41 is contained inside the absorbent body 4. As the absorbent sheet, the adhesive force generated in the superabsorbent polymer 41 in a wet state or a binder such as an adhesive or an adhesive fiber added separately is used between the constituent fibers containing pulp and the superabsorbent polymer 41. A sheet-like material obtained by bonding the fiber and the constituent fiber containing pulp to each other can be preferably used. The absorbent sheet is an absorbent body molded into a sheet shape, and is generally distinguished from an absorbent body having a fiber stack type structure in which absorbent materials are stacked. Typical absorbent sheets include those described in Japanese Patent No. 2963647 and those described in Japanese Patent No. 2955223.

The superabsorbent polymer 41 contained in the absorber 4 is generally in the form of particles, but may be in the form of fibers. When a particulate superabsorbent polymer is used, its shape may be spherical, lumpy, bale-shaped or amorphous. As the superabsorbent polymer, generally, a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof. Sodium salt can be preferably used as the polyacrylate or polymethacrylate. Further, acrylic acid or methacrylic acid may be converted into maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, 2-(meth)acryloylethanesulfonic acid, 2-hydroxyethyl(meth)acrylate, styrenesulfonic acid, or the like. It is also possible to use a copolymer obtained by copolymerizing the above comonomer within a range not deteriorating the performance of the superabsorbent polymer.

Examples of the pulp-containing constituent fibers of the absorbent body 4 include crosslinked cellulose fibers (pulp fibers) in which the inside or the inside of cellulose is crosslinked with a suitable crosslinking agent. Further, this constituent fiber may contain regenerated cellulose fiber such as rayon fiber having an improved crystallinity of cellulose. Further, the constituent fibers may contain synthetic fibers. The synthetic fibers are preferably thermoplastic fibers, for example. As the thermoplastic fiber, for example, a single fiber formed of a single synthetic resin such as polyethylene, polypropylene, polyester, polyurethane, or a synthetic resin such as a composite of two or more kinds of these is used. Examples include composite fibers.

In the napkin 1, the multilayer structure formed of the absorbent sheet may be formed by stacking a plurality of absorbent sheets, or may be formed by folding one absorbent sheet. Or may be formed by combining these. In the napkin 1, as shown in FIGS. 3 and 4, the absorbent body 4 includes a central absorbent sheet 402 formed of an absorbent sheet and a central absorbent sheet 402 in the excretion part facing portion B of the wearer when worn. It is composed of a main body absorbent sheet 401 which covers. That is, the absorbent body 4 of the napkin 1 is formed with a multi-layer structure including the main body absorbent sheet 401 and the central absorbent sheet 402, and the middle-height portion 403 is formed in the excretion portion facing portion B. The multilayer structure of the absorbent body 4 of the napkin 1 has a structure in which the central absorbent sheet 402 is included inside the folded structure of one main body absorbent sheet 401, and the central absorbent sheet 402 has the middle high portion 403. It is located in. In the diaper 1, the multilayer structure of the absorbent body 4 thus formed is arranged on the skin-facing surface of the hemagglutination agent-containing sheet 80.

Preferably, in the napkin 1, as shown in FIGS. 3 and 4, the main body absorbent sheet 401 is made of one sheet having a length (width) in the lateral direction Y longer than that of the napkin 1, and the main body absorbent sheet 401 Both sides of the absorbent sheet 401 along the longitudinal direction X are folded back to the back sheet 3 side to form a two-layer structure, and both side edges along the longitudinal direction X are overlapped at the center of the transverse direction Y to form the absorbent body 4. Forming the outer shape. As described above, the main body absorbent sheet 401 forming the two-layer structure has the front surface side absorbent sheet 401a on the top surface sheet 2 side and the back surface side absorbent sheet 401b on the back surface sheet 3 side. The central absorbent sheet 402 is composed of one sheet having a rectangular shape in plan view, and has a three-layer structure in which the central absorbent sheet 402 is folded in three in the lateral direction Y. When the central absorbent sheet 402 is formed into a three-layer structure, in the two fold lines that traverse the central absorbent sheet 402 in the vertical direction X, the second fold line counted from the free end in the horizontal direction Y is used. At the back sheet 3 side, and further at the first fold line counting from the free end in the lateral direction Y to the top sheet 2 side, and the free end in the lateral direction Y is arranged inside the three-layer structure. Fold it down like a spiral. As described above, the central absorbent sheet 402 forming the three-layer structure folded in three in a spiral shape includes the upper absorbent sheet 402a on the front absorbent sheet 401a side and the lower absorbent sheet on the back absorbent sheet 401b side. It has a sheet 402b and an intermediate absorbent sheet 402c between the sheets 402a and 402b. The middle-high section 403 sandwiches a sheet having a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b between a front absorbent sheet 401a and a back absorbent sheet 401b. It is formed and has a five-layer structure. The middle height portion 403 of the five-layer structure is formed only in the excretion portion facing portion B, and is not formed in the front portion A and the rear portion C. As shown in FIG. 3, the absorbent sheet constituting the absorbent body 4 in the middle-high section 403 is different from the absorbent sheet constituting the absorbent body 4 in the middle-high section 403 in contrast to the two-layer structure in which the number of laminated absorbent sheets constituting the absorbent body 4 is two. This is a five-layer structure in which the number of laminated sheets of the property sheet is 5, and the number of laminated sheets is large and the thickness is large. Therefore, the middle-high portion 403 is a protruding portion that protrudes toward the surface sheet 2 side (skin-facing surface side of the napkin 1) in the excretion portion facing portion B.

As described above, in the napkin 1, as shown in FIGS. 3 and 4, around the middle height portion 403 of the absorbent body 4, the hemagglutination agent-containing sheet 80 is provided on the skin-facing surface of the hemagglutination agent-containing sheet 80. A two-layer structure including two absorbent sheets (a front-side absorbent sheet 401a and a back-side absorbent sheet 401b) is arranged adjacent to the skin facing surface. Then, in the middle-high part 403 of the absorbent body 4, on the skin-facing surface of the hemagglutination agent-containing sheet 80, adjacent to the skin-facing surface of the hemagglutination agent-containing sheet 80, five absorbent sheets (front-side absorption The five-layer structure including the absorbent sheet 401a, the back-side absorbent sheet 401b, the upper absorbent sheet 402a, the lower absorbent sheet 402b, and the intermediate absorbent sheet 402c is arranged.

The thickness of each absorbent sheet is preferably 0.1 mm or more, particularly 0.3 mm or more, and preferably 2 mm or less, particularly 1.5 mm or less. More specifically, it is preferably 0.1 mm or more and 2 mm or less, and particularly preferably 0.3 mm or more and 1.5 mm or less from the viewpoint of obtaining an absorbent article having a good wearing feeling.

The thickness of the absorbent body 4 in the middle and high portion 403 is preferably 0.7 mm or more, more preferably 1 mm or more, and preferably 5 mm or less, more preferably 4 mm or less, and more specifically, preferably It is 0.7 mm or more and 5 mm or less, and more preferably 1 mm or more and 4 mm or less. By setting the thickness of the middle height portion 403 in such a range, it becomes easy to achieve both good wearing feeling and high absorption performance in the excretion part facing portion B in which the middle height portion 403 is formed. Further, when the absorbent article is provided with the wing portion as in the napkin 1 of the present embodiment, it becomes easy to suppress the twisting of the absorbent body at the excretion portion facing portion during wearing. The absorber has a thickness in a portion other than the middle-high portion 403 of preferably 0.3 mm or more, more preferably 0.5 mm or more, and preferably 3 mm or less, more preferably 2.5 mm or less, More specifically, it is preferably 0.3 mm or more and 3 mm or less, and more preferably 0.5 mm or more and 2.5 mm or less. This range is preferable from the viewpoint of high absorption performance and enhancing the followability to the movement of the wearer. The thickness of the absorbent body and the absorbent sheet is measured by the following method.

<Measuring method of thickness of absorbent sheet and absorbent body>
The absorbent sheet or the absorbent body, which is the object of measurement, is allowed to stand on a horizontal place without wrinkles or bending, and the thickness is measured under a load of 5 cN/cm ² . A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) was used for measuring the thickness in the present invention. At this time, a plate having a circular shape or a square shape in plan view (an acrylic plate having a thickness of about 5 mm) is arranged between the tip portion of the thickness gauge and the measurement portion of the measurement object, and the load is 5 cN/cm ² . Adjust the plate size so that

In the napkin 1, as shown in FIGS. 1 to 4, the multilayer structure of the absorber 4 has a plurality of slits 44. With the slit 44, blood can be diffused. In the napkin 1, the excretion portion facing portion B of the absorbent body 4 is provided with a slit 44 extending in the vertical direction X in plan view as shown in FIGS. The slits 44 facilitate the diffusion of menstrual blood that has reached the absorber 4 in the longitudinal direction X, and also facilitates the permeation of the menstrual blood in the thickness direction of the absorber 4. In the napkin 1, as shown in FIG. 2, when viewed in a plan view, the slits 44 extending in the vertical direction X have slit regions 44S formed in a state of being dispersed in both the vertical direction X and the horizontal direction Y. As shown in FIG. 2, the slit region 44S in which the plurality of slits 44 are arranged extends not only to the excretion part facing portion B but also to a part of the front part A and a part of the rear part C. That is, the slit 44 exists at least in the excretion part facing portion B, and a region including the slit 44 located in the excretion part facing portion B is referred to as a slit region 44S.

In the napkin 1, the arrangement of the slits 44 in the slit region 44S is not particularly limited as long as the slits 44 are arranged in both the vertical direction X and the horizontal direction Y, but the central slit region 44S1 includes: It is preferable that four or more slits are dispersedly arranged. The central slit region 44S1 is a region of the slit region 44S that overlaps with the central absorbent sheet 402.
In the central slit region 44S1, three or more slit rows are preferably formed in the vertical direction X, more preferably four or more rows, and even more preferably five or more rows. Further, the number of slits 44 included in each slit row and separated in the lateral direction Y is preferably 2 or more, and more preferably 3 or more.
In the vertical direction X of the slit area 44S, it is preferable to have one row or two or more slit rows before and after the central slit area 44S1 in the vertical direction X, in addition to the slit rows included in the central slit area 44S1.

The slit 44 may be formed so as to penetrate at least the back-side absorbent sheet 401b which is an absorbent sheet adjacent to the skin-facing surface of the hemagglutination agent-containing sheet 80 in which the hemagglutination agent 8 is arranged. In the napkin 1, as shown in FIGS. 3 and 4, the multilayer structure of the absorbent body 4 is cross-sectionally viewed, and all layers of the multilayer structure of the absorbent body 4 are penetrated in the thickness direction thereof. Suitably, in the napkin 1, the slits 44 are, in the excretion part facing portion B, five laminated sheets constituting the middle-high part 403, that is, the front-side absorbent sheet 401a, the upper-side absorbent sheet 402a, and the intermediate absorbent sheet. The sheet 402c, the lower absorbent sheet 402b, and the back absorbent sheet 401b all penetrate, and the hemagglutination agent-containing sheet 80 also penetrates. Further, in the napkin 1, in a part of the front part A and a part of the rear part C, the slits 44 penetrate the front-side absorbent sheet 401a and the back-side absorbent sheet 401b, and contain a hemagglutination agent. The seat 80 also penetrates. Thus, in the napkin 1, the slit 44 penetrates the multilayer structure of the absorber 4 and the hemagglutination agent-containing sheet 80. In the napkin 1, all the slits 44 penetrate the multilayer structure of the absorbent body 4 and the hemagglutination agent-containing sheet 80, but at least one slit 44 has the multilayer structure of the absorbent body 4 and the hemagglutination agent. It is preferable to penetrate the containing sheet 80.

In the napkin 1, as shown in FIGS. 3 and 4, the multilayer structure of the absorbent body 4 is viewed in cross section, and the layers are not joined at the peripheral portion of the multilayer structure divided by each slit 44. Preferably, in each slit portion 44P in which each slit 44 is arranged, the layers of the multilayer structure are not joined. Here, the slit portion 44P is a portion that includes the slit 44 and the constituent members of the absorber 4 that are separated by the slit 44 and that are present in the peripheral portion of the slit. In other words, the slit portion 44P is meant to include the slit 44 and a wall-like multilayer structure portion which is a peripheral edge portion forming a space divided by the slit 44. Specifically, in the napkin 1, the multilayer structure of the excretion part facing portion B is cross-sectionally viewed, and in each slit portion 44P, between the surface side absorbent sheet 401a and the upper side absorbent sheet 402a, the upper side absorbent sheet. The interlayer between the 402a and the intermediate absorbent sheet 402c, the interlayer between the intermediate absorbent sheet 402c and the lower absorbent sheet 402b, and the interlayer between the lower absorbent sheet 402b and the back absorbent sheet 401b are not joined. Further, the layers between the back-side absorbent sheet 401b and the hemagglutination agent-containing sheet 80 are also not joined. In the napkin 1, a cross-sectional view of a part of the front part A and a part of the rear part C of the multilayer structure is seen, and in each slit part 44P, the slit 44 has a front-side absorbent sheet 401a and a back-side absorbent property. The interlayer between the sheet 401b and the back-side absorbent sheet 401b and the hemagglutination agent-containing sheet 80 are also non-bonded.

Further, in the napkin 1, as shown in FIGS. 1 and 2, when the multilayer structure of the absorber 4 is viewed in a plan view, the multilayer structure includes the slit portions 44P in which the slits 44 are arranged and the slit portions 44P. Other than the non-slit portion 44N, the fiber density of the slit portion 44P, specifically, the fiber density of the peripheral portion of the slit 44 is higher than the fiber density of the non-slit portion 44N. Since the slit portion 44P, which is the cut portion of the slit 44, is slightly compressed when the slit 44 is formed by cutting and processing, the density is higher than that of the non-slit portion 44N in which the slits 44 other than the slit portion 44P are not provided. It's getting higher.

In the napkin 1, each slit 44 is formed such that the opening width WU44 on the side of the topsheet 2 is smaller than the opening width WD44 on the side of the backsheet 3, as shown in FIG. The opening width WU44 on the surface sheet 2 side in the slit 44 is preferably 0.05 mm or more, more preferably 0.7 mm or more, and preferably 1.2 mm or less, more preferably 1.0 mm or less, and Specifically, it is preferably 0.05 mm or more and 1.2 mm or less, and more preferably 0.07 mm or more and 1.0 mm or less. The opening width WD44 of the slit 44 on the back sheet 3 side is preferably 0.1 mm or more, more preferably 0.2 mm or more, and preferably 1.5 mm or less, more preferably 1.2 mm or less. More specifically, it is preferably 0.1 mm or more and 1.5 mm or less, and more preferably 0.2 mm or more and 1.2 mm or less. The opening width of the slit 44 of the absorber 4 described above is measured by the following method.

<Measuring method of opening width of slit 44>
The opening width of the slit 44 is obtained by taking out the absorber 4 from the napkin 1, placing the taken-out absorber 4 horizontally, adjusting the measurement magnification with a Keyence digital microscope VHX-900, and expanding it. taking measurement.

The length (longitudinal length) L44 (see FIG. 2) of the slit region 44S in a plan view is preferably 10 mm or more, more preferably 15 mm or more, and preferably 35 mm or less, further preferably. Is 25 mm or less, preferably 10 mm or more and 35 mm or less, and more preferably 15 mm or more and 25 mm or less.
The spacing (widthwise spacing) D44 of the slits 44 in the same slit row in the slit region 44S is preferably 3 mm or more, more preferably 7 mm or more, preferably 20 mm or less, more preferably 15 mm or less, and also preferably. Is 3 mm or more and 20 mm or less, more preferably 7 mm or more and 15 mm or less.

The forming material of each component of the napkin 1 of the present embodiment described above will be described.

As the topsheet 2, a non-woven fabric having a single-layer or multi-layer structure, a perforated film or the like can be used, but a topsheet made of non-woven fabric treated with a hydrophilizing agent can be preferably used. As the hydrophilizing agent, various ones conventionally used in absorbent articles such as sanitary napkins can be used without particular limitation. In the napkin 1, the sheet having the uneven structure shown in FIG. 5 is used. FIG. 5 shows an enlarged main part of the skin-facing surface of the topsheet 2 in the napkin 1. On the skin-facing surface 2a of the topsheet 2 (skin-facing surface of the napkin 1), recesses 20 extending in a direction intersecting the vertical direction X and the horizontal direction Y (that is, an oblique direction) are formed in an oblique lattice pattern. The surface sheet 2 is divided into a large number of regions by the recesses 20, and a large number of divided regions 22 are formed. In the embodiment shown in FIG. 5, the recess 20 is formed over the entire surface sheet 2. Instead of this, the recessed portion 20 may be formed at least in the excretion portion facing portion B. Note that the X direction in FIG. 5 is the same as the direction (CD) orthogonal to the sheet flow direction at the time of manufacturing the topsheet, and is also the same as the longitudinal direction X (see FIG. 1) of the napkin 1. Further, the Y direction in FIG. 5 is the same as the sheet flow direction (MD) at the time of manufacturing the topsheet, and the same as the lateral direction Y (see FIG. 1) of the napkin 1.

Explaining the surface sheet 2 further, the surface sheet 2 is made of a fiber sheet such as a non-woven fabric having a single-layer structure or a multi-layer structure, and the entire skin-facing surface 2a thereof is formed in an oblique lattice shape as shown in FIG. It has a concave-convex shape having a large number of concave portions 20 and a plurality of convex portions 21 surrounded by the concave portions 20. On the other hand, the non-skin-facing surface 2b of the topsheet 2 has substantially no uneven shape and is substantially flat.

The hollow portion 20 is formed by pressing or adhering the constituent fibers of the topsheet 2 made of a fiber sheet. Examples of means for crimping the fibers include squeezing processing with or without heat, and embossing processing such as ultrasonic pressing processing. As a result, in the surface sheet 2, the density of the depressions 20 is higher than the density of the projections 21. Due to this, when the external force is applied to the topsheet 2, the recess 20 easily acts as a flexible shaft for deformation. The hollow portion 20 in the topsheet 2 according to the present embodiment is formed by subjecting a fiber web formed by the card method to hot embossing. In the hollow portion 20, the heat-fusible fibers that are the constituent fibers of the topsheet 2 or the nonwoven fabric that constitutes the topsheet 2 are integrated by heat-sealing. In the heat-fusible fiber in the hollow portion 20, the heat-fusible component is melted and the fiber form is not maintained.

In the topsheet 2, the recessed portion 20 is formed only in the topsheet 2, and is not formed in the absorber 4 arranged below the topsheet 2 and adjacent to the topsheet 2. Therefore, the topsheet 2 and the absorber 4 are not joined via the recess 20.

The recess 20 is preferably linear. Here, the “linear shape” is not limited to the straight line as shown in FIG. 5 in which the shape of the depression 20 is a plan view, and includes a curved line, and each line may be a continuous line, or a rectangle, a square, a rhombus in a plan view. Alternatively, a large number of concave portions (embossed portions) such as circles and crosses may be continuously arranged without any interval to form a continuous line as a whole. The phrase "without substantial spacing" means that the spacing between adjacent recesses is within 5 mm.

The depressions 20 are formed in an oblique lattice shape as shown in FIG. More specifically, the surface sheet 2 is formed as the recesses 20 in parallel with each other and with a large number of first linear recesses 20a formed at predetermined intervals. In addition, the first linear recess 20a and the second linear recess 20b intersect each other at a predetermined angle. Each of the first linear recess 20a and the second linear recess 20b linearly extends in a direction intersecting the vertical direction X and the horizontal direction Y (that is, an oblique direction). The width of the first linear depression 20a and the width of the second linear depression 20b may be the same or different. The distance between the first linear depressions 20a and the distance between the second linear depressions 20b may be the same or different.

Each of the divided areas 22 is an area surrounded by the linear depression 20 and has a rhombic shape in a plan view. Area of each divided area 22 is preferably, for example, 0.25 cm ² or more 2 cm ² or less. The partitioned area 22 may have a rhombus shape that is longer in the horizontal direction Y than in the vertical direction X in a plan view. Alternatively, conversely, a rhombus shape that is longer in the vertical direction X than in the horizontal direction Y can be used. When the partitioned region 22 has a shape that is long in the lateral direction Y of the napkin 1, the topsheet 2 in which a large number of recesses 20 are formed retains high rigidity in the lateral direction Y. As a result, twisting and wrinkles in the mounted state of the napkin 1 are effectively prevented. The twisting and wrinkling of the napkin 1 in the mounted state are mainly caused by the napkin 1 sandwiched between the thighs of the wearer being pressed in the lateral direction Y by the thighs. Has a high rigidity in the lateral direction Y, the shape of the napkin 1 is likely to be maintained even when pressed in the lateral direction Y, and twisting and wrinkling are less likely to occur.

Each of the divided regions 22 is formed with a convex portion 21 that is relatively raised with respect to the hollow portion 20 surrounding the divided region 22, and each of the divided regions 22 has a convex portion 21a provided on the skin facing surface 2a side. It has a shape. The top 21 a of the protrusion 21 is located at the center of the partitioned area 22. The inside of the convex portion 21 is filled with the constituent fibers of the topsheet 2. In the present invention, the recesses other than the linear recesses are not excluded, but the linear recesses are preferable from the viewpoint of excellent formation of the protrusions 21.

In this way, the depressions 20 and the projections 21 are alternately arranged in the vertical direction X and the horizontal direction Y of the topsheet 2, thereby reducing the contact area of the napkin 1 with the wearer's skin. It effectively prevents stuffiness and rash. Further, the convex portion 21 (partitioned region 22) is surrounded by the hollow portion 20 and has a closed shape in a plan view, so that the convex portion 21 is not surrounded by the hollow portion 20, Since the constituent fibers in the convex portion 21 are likely to expand in the thickness direction of the topsheet 2, the thickness of the convex portion 21 increases, whereby 1) the liquid quickly permeates and the liquid remains little, and thus the topsheet 2 The contact area with the skin is reduced, and 2) the convex portions 21 are formed in a regular pattern, so that the visual impression is improved, and the like.

Instead of the above-mentioned structure as the concavo-convex structure surface sheet, the concavo-convex structure surface sheet having a hollow convex part, and a ridge part in which the convex part and the concave part respectively extend in the longitudinal direction or the lateral direction of the napkin 1 It may be a surface sheet which is a groove. However, from the viewpoint of absorption of menstrual blood, the uneven surface sheet having the solid structure described above is preferable.

As the back sheet 3, various materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation, and a moisture-permeable resin film or a moisture-impermeable resin film can be used. ..

The hemagglutination agent-containing sheet 80 is preferably made of a hydrophilic non-woven fabric or a hydrophilic fiber aggregate. Examples of the non-woven fabric include an air-through non-woven fabric, a point bond non-woven fabric, a resin bond non-woven fabric, a spun lace non-woven fabric, and an air-laid non-woven fabric.
The hemagglutination agent-containing sheet 80 preferably has a grammage higher than that of the topsheet 2, from the viewpoint of quickly drawing menstrual blood during use of the napkin 1, specifically, preferably 10 g/m ^2. It is 50 g/m ² or less and more preferably 15 g/m ² or more and 40 g/m ² or less.

In the napkin 1, it is preferable that an adhesive is applied and fixed between the topsheet 2 and the absorber 4 and between the hemagglutination agent-containing sheet 80 or the absorber 4 and the backsheet 3. The adhesive can be applied using a known means, for example, a slot coat gun, a spiral spray gun, a spray gun, or a dot gun. In the napkin 1, it can be applied spirally using a spiral spray gun. preferable. As the adhesive to be applied, for example, a hot melt adhesive is preferably used. The coating amount of the hot melt adhesive is preferably 1.5 g/m ² or more and 10 g/m ² or less.

Further, like the napkin 1, in order to form the slits 44 in the absorbent body 4, the multilayer structure of the absorbent sheet may be partially cut by a known cutting means. For example, on the circumferential surface of the roll, It is possible to use a cutting device including a cutter roll having a large number of cutting blades extending in the circumferential direction dispersed in the circumferential direction and the axial direction of the roll, and an anvil roll for receiving the blade of the cutter roll.

The effect and estimation mechanism of the napkin 1 described above will be described. As shown in FIG. 4, the napkin 1 includes a hemagglutination agent-containing sheet 80 containing the hemagglutination agent 8. Therefore, during the use of the napkin 1, the hemagglutination agent 8 contained in the hemagglutination agent-containing sheet 80 can separate menstrual blood into red blood cells and plasma. The aggregate formed by aggregating the separated red blood cells is likely to be retained in the hemagglutination agent-containing sheet 80, and the separation of red blood cells and plasma is facilitated. Since the multilayer structure of the absorbent body 4 formed of the absorbent sheet is arranged on the skin-facing surface of the hemagglutination agent-containing sheet 80, the separated plasma is a multilayer of the absorbent body 4 containing pulp. It is easy to diffuse in the plane direction of each absorbent sheet through the interface between the adjacent absorbent sheets forming the structure, and it is easy to retain a large amount. Therefore, the plasma can be retained by effectively utilizing the absorber 4, so that the plasma retention amount increases. Further, when the separated blood plasma is easily retained in a large amount by utilizing the interface of the multilayer structure, the content of the superabsorbent polymer 41 can be suppressed, it is difficult to impair the wearing feeling, and the body fluid can be swiftly and sufficiently supplied. It can be absorbed, and it is possible to effectively prevent the body fluid once absorbed from returning.

Further, in the napkin 1, as shown in FIG. 4, a plurality of slits 44 for diffusing blood are formed in the multilayer structure of the absorber 4. Therefore, during use of the napkin 1, menstrual blood easily flows to the hemagglutination agent 8 of the hemagglutination agent-containing sheet 80, and the shed menstrual fluid is further separated into red blood cells and plasma by the hemagglutination agent 8, and Can be absorbed more quickly and sufficiently, and the body fluid once absorbed can be more effectively prevented from returning. The effect is exhibited when the absorber 4 has the slit 44 and the hemagglutination agent-containing sheet 80 that communicates with the slit 44 is present. However, as shown in FIGS. 3 and 4, when the absorbent body 4 has a multi-layer structure and the multi-layer structure of the absorbent body 4 is arranged on the skin-facing surface of the hemagglutination agent-containing sheet 80, The effect is even higher. Further, when the multilayer structure of the absorber 4 is viewed in cross section, the layers of the multilayer structure are not joined at the peripheral edge portion of the slit 44 that constitutes each slit portion 44P in which each slit 44 is arranged. Therefore, the separated plasma is more likely to diffuse to each interface of the multilayer structure of the absorbent body 4 containing pulp, and more easily retained. In addition, since the fiber density of the slit portion 44P is higher than the fiber density of the non-slit portion 44N, menstrual blood is likely to collect in the slit portion 44P due to the density gradient, and the hemagglutination agent 8 of the hemagglutination agent-containing sheet 80 is collected. It is easier for menstrual blood to flow.

Further, in the napkin 1, as shown in FIG. 4, each slit 44 is formed such that the opening width WU44 on the surface sheet 2 side is smaller than the opening width WD44 on the back sheet 3 side. Therefore, even if the mounting pressure is applied during use of the napkin 1, it is difficult for the separated plasma to return from the back sheet 3 side to the top sheet 2 side, and it is possible to more effectively prevent the fluid return of the body fluid once absorbed. it can.

Further, in the napkin 1, as shown in FIGS. 3 and 4, the slit 44 penetrates not only the multilayer structure of the absorber 4 but also the hemagglutination agent-containing sheet 80. Therefore, menstrual blood can be easily taken into the hemagglutination agent-containing sheet 80, and the taken menstrual blood can be further separated into red blood cells and plasma. In addition, it is easy to hold the aggregate formed by the separated red blood cells in the hemagglutination agent-containing sheet 80, and it is easy to hold the separated plasma in the hemagglutination agent-containing sheet 80. It can be effectively prevented. From the viewpoint of effectively preventing the body fluid from returning, the slits 44 formed in the hemagglutination agent-containing sheet 80 are also formed such that the opening width on the side of the top sheet 2 is smaller than the opening width on the side of the back sheet 3. Preferably.

Although the present invention has been described above based on its preferred embodiment, the sanitary absorbent article of the present invention is not limited to the napkin 1 of the above embodiment and can be appropriately modified.
For example, in the napkin 1, as shown in FIG. 4, the entire multilayer structure of the absorbent body 4 formed of the absorbent sheet is arranged on the skin-facing surface of the hemagglutination agent-containing sheet 80. It suffices if the structure is arranged, and for example, as shown in FIG. 6, a part of the multilayer structure of the absorbent body 4 formed of the absorbent sheet may be arranged. In the hemagglutination agent-containing sheet 80 and the absorbent body 4 shown in FIG. 6, the hemagglutination agent-containing sheet 80 is arranged inside the absorbent body 4 of the multilayer structure. Preferably, as shown in FIG. 6, the center of the three-layer structure including the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b on the skin-facing surface of the hemagglutination agent-containing sheet 80. The absorbent sheet 402 is arranged, and the whole of them is formed by being wrapped with the main body absorbent sheet 401. Specifically, on the non-skin facing surface of the hemagglutination agent-containing sheet 80, the central side absorbent sheet 402 of the three-layer structure and the surface side absorbent sheet 401a constituting the main body absorbent sheet 401 are arranged, A four-layer structure of the absorbent body 4 formed of an absorbent sheet is arranged. On the non-skin-facing surface of the blood cell aggregating agent-containing sheet 80, a back side absorbent sheet 401b constituting the main body absorbent sheet 401 is arranged. According to the napkin 1 including the hemagglutination agent-containing sheet 80 and the multilayer structure of the absorbent body 4 shown in FIG. 6, the same effect as that of the napkin 1 shown in FIG. 4 described above can be obtained.

Further, in the napkin 1, as shown in FIG. 4, a plurality of slits 44 for diffusing blood are formed in the multilayer structure of the absorbent body 4, but the slits 44 may not be formed.

Further, as shown in FIG. 4, the absorbent sheet that constitutes the absorbent body 4 is formed of a two-layer region of the polymer-rich region PT and the fiber-rich region FT, but the polymer-rich region PT and the fiber-rich region FT are It may not be formed, and may be formed in three or more layers having the polymer rich region PT and the fiber rich region FT.

In the sanitary absorbent article of the present invention, a second sheet made of a non-woven fabric may be arranged between the topsheet 2 and the absorbent body 4. The width (length in the lateral direction Y) of the second sheet is preferably shorter than the width (length in the lateral direction Y) of the absorbent body 4, and the length in the longitudinal direction X is the longitudinal direction of the absorbent body 4. It is preferable that it is longer than the length of X and is arranged over the entire length of the napkin in the vertical direction X. The second sheet is a sheet that is separate from the topsheet 2 and the absorber 4 and is also called a sublayer sheet in the technical field, and is provided in a stripe shape or a spiral shape with the topsheet 2 and/or the absorber 4. It has a joint part partially joined by an adhesive or the like. The second sheet is a sheet that plays a role of improving the permeability of the liquid from the topsheet 2 to the absorber 4 and reducing the liquid return of the liquid absorbed by the absorber 4 to the topsheet 2.

Further, regarding the compressed groove 9, instead of the napkin of the present embodiment, a vertical groove extending in the vertical direction X while forming a convex curved shape in the horizontal direction Y inward in the groove shape of the excretion part facing portion B. In other words, the groove shape in the front part A and the rear part C may be a straight line shape or a compressed groove shape in which a concave curved shape is directed inward in the lateral direction Y.

Further, as the absorbent body, instead of the absorbent sheet, an absorbent body having a pile-type structure in which hydrophilic fibers such as pulp and absorbent materials such as superabsorbent polymers are stacked may be used.

The sanitary absorbent article for absorbing menstrual blood of the present invention may be a sanitary napkin, a panty liner (carriage sheet), or the like.

1 Sanitary napkins (sanitary absorbent articles)
2 Topsheet 3 Backsheet 4 Absorber 401 Main body Absorbent sheet 401a Front side absorbent sheet 401b Backside absorbent sheet 402 Central absorbent sheet 402a Upper absorbent sheet 402b Lower absorbent sheet 402c Intermediate absorbent sheet 41 High absorption Polymer 44 Slit 8 Hemagglutination agent 80 Hemagglutination agent-containing sheet 9 Squeeze groove 91 First lateral squeeze groove 92 Vertical squeeze groove 93 Second lateral squeeze groove FT Fiber rich region PT Polymer rich region

Claims (3)

An absorbent article containing pulp, and a sanitary absorbent article comprising a top sheet and a back sheet that are located on the side of the wearer's skin facing surface that sandwiches the absorber,
Between the topsheet and the backsheet, a hemagglutination agent-containing sheet containing a hemagglutination agent,
The absorber is formed of an absorbent sheet,
On the skin facing surface of the hemagglutination agent-containing sheet, a multilayer structure formed of the absorbent sheet is arranged ,
A sanitary absorbent article having a slit that penetrates the multilayer structure and the hemagglutination agent-containing sheet . The multilayer structure has a plurality of slits,
In a cross-sectional view of the multilayer structure, in the peripheral portion of the multilayer structure divided by each slit, the layers of the multilayer structure are not joined,
In a plan view of the multilayer structure, the multilayer structure is divided into each slit portion where each slit is arranged and a non-slit portion other than the slit portion, and the fiber density of the slit portion is the non-slit portion. The sanitary absorbent article according to claim 1, which has a fiber density higher than that of the slit portion. The multilayer structure has a plurality of slits,
The sanitary absorbent article according to claim 1 or 2, wherein the slit has an opening width on the surface sheet side smaller than an opening width on the back sheet side.

Images